Canada · Delayed Price · Currency is CAD DRI Healthcare Trust Earnings Call Transcripts
Fiscal Year 2026
-
The meeting confirmed quorum, elected eight trustees, and approved all motions including auditor reappointment, a carried interest plan, and a unit increase amendment. Record operating results and strategic financial initiatives were highlighted, with a focus on growth and innovation in 2026.
-
Q1 2026 saw record income and EBITDA margin, driven by strong royalty growth and disciplined expense management. Balance sheet strength improved via debt refinancing, while portfolio assets like ORSERDU and EKTERLY outperformed. Royalty market growth and capital flexibility support a positive outlook.
Fiscal Year 2025
-
Record 2025 results featured 6% income growth, margin expansion, and robust capital returns. Guidance for 2026 and beyond targets low teens EBITDA CAGR, supported by a strong pipeline, disciplined capital allocation, and continued operational improvements.
-
Q3 saw double-digit cash receipt growth, strong EBITDA margins, and a major royalty acquisition in the TED market. Portfolio diversification and disciplined capital allocation support robust cash flows, while cost optimization and new product launches position for future growth.
-
Internalization of management completed, expected to save $200M over 10 years and improve governance. Q2 2025 cash receipts were $40.2M, with Orserdu and Xolair outperforming, while Bonjour and Omidria faced reimbursement headwinds. Ectorly FDA approval adds a new growth driver.
-
Strong Q1 results featured high cash receipts and income, despite a slight year-over-year decline due to prior milestone payments. The internalization of management is expected to save over $200M in fees over 10 years, with enhanced governance and capital flexibility.
Fiscal Year 2024
-
Record financial results in 2024 included 45% growth in cash receipts and 37% higher adjusted EBITDA, driven by four major transactions and portfolio expansion. 2025 guidance anticipates further income growth, with a strong deal pipeline and improved governance and capital structure.
-
Strong year-over-year growth in cash receipts and income was driven by new transactions and portfolio expansion. Credit facilities were increased, and the company remains well-capitalized with a robust deal pipeline. Guidance updates and internalization decisions are expected in Q4.
-
Q2 2024 saw strong financial growth with 50% higher cash receipts and a 77% adjusted EBITDA margin. Leadership changes and internal control remediation followed an investigation, but business execution and capital deployment remain robust, with a positive outlook and no equity raise needed.